List view / Grid view
A new computer-based approach could help clinicians select the best combinations of broadly neutralising antibodies to treat HIV based on the virus’ genetics, while minimising the risk of the virus escaping treatment.
Researchers have discovered how immune system dendritic cells are key to maintaining and regulating response to immunotherapy.
Scientists at Northwestern Medicine have developed new techniques in human blood to pave potential paths towards a HIV cure.
A recent study has shown that antiretroviral therapy timing impacts the animal version of HIV and latent tuberculosis.
A new potential mRNA vaccine that delivers instructions for making two key HIV proteins has been tested in mice and rhesus macaques.
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
The CRISPR-based therapy called EBT-101 excised HIV proviral DNA from the genomes of different cells and tissues in human cells and mice.
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
Scientists have used exosomes to deliver a novel protein that prevented HIV from replicating in the bone marrow, spleen and brain of mouse models.
Stanford researchers have developed a multi-purpose “mini” CRISPR system, called CasMINI, that may be easier to deliver into human cells.
Researchers have identified a process that amplifies changes in gene expression, which could be harnessed to accelerate stem cell differentiation.
Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.
In non-human primates, researchers have found that mesenchymal stem cells were effective at strengthening the immune response to HIV.
A new pre-clinical mouse model could enable the study of HIV infection and the testing of cell therapies against the virus.
